Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naive patients with moderate-to-severe plaque psoriasis: a randomized controlled trial.

ABSTRACT:

Background

Fumaric acid esters (FAEs; Fumaderm^® ) are the most frequently prescribed first-line systemic treatment for moderate-to-severe plaque psoriasis in Germany. Risankizumab (Skyrizi^® ) is a humanized IgG1 monoclonal antibody that specifically binds to the p19 subunit of interleukin 23.

Objectives

To compare risankizumab treatment to FAEs in patients with psoriasis.

Methods

This phase III randomized, active-controlled, open-label study with blinded assessment of efficacy was conducted in Germany. Patients were randomized (1 : 1) to subcutaneous risankizumab 150 mg (weeks 0, 4 and 16) or oral FAEs at increasing doses from 30 mg daily (week 0) up to 720 mg daily (weeks 8-24). Enrolled patients were adults naïve to and candidates for systemic

SUBMITTER: Thaci D 

PROVIDER: S-EPMC9291944 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature